Effects of two different immunotherapies on triple negative breast cancer in animal model

Cellular Immunology

Volumn 284, Issue 1-2, 2013, Pages 111-118

  Liu, Xiaoyi ^a   Hu, Jianxia ^a   Cao, Weihong ^a   Qu, Huili ^a   Wang, Yu ^a   Ma, Zhongliang ^a   Li, Funian ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Breast cancer; CpG; DC CIK cells; GM CSF; Immunotherapy; Triple negative breast cancer

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CANCER STEM CELL; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; DENDRITIC CELL; DRUG EFFECT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THERAPY EFFECT; TRIPLE NEGATIVE BREAST CANCER;

BREAST CANCER; CPG; DC/CIK CELLS; GM-CSF; IMMUNOTHERAPY; TRIPLE NEGATIVE BREAST CANCER;

ANIMALS; CYTOKINE-INDUCED KILLER CELLS; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; IMMUNOTHERAPY; IMMUNOTHERAPY, ADOPTIVE; KAPLAN-MEIER ESTIMATE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; OLIGODEOXYRIBONUCLEOTIDES; RANDOM ALLOCATION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84882960220     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2013.07.018     Document Type: Article

References (49)

1. De Brot M., Rocha R.M., Soares F.A., Gobbi H. Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers. Pathology 2012, 44:303-312.
2. Xu L., Yin S., Banerjee S., Sarkar F., Reddy K.B. Enhanced anticancer effect of the combination of cisplatin and TRAIL in triple-negative breast tumor cells. Mol. Cancer Ther. 2011, 10:550-557.
3. Chougule M.B., Patel A.R., Jackson T., Singh M. Antitumor activity of noscapine in combination with doxorubicin in triple negative breast cancer. PLoS ONE 2011, 6:e17733.
4. Foulkes W.D., Smith I.E., Reis-Filho J.S. Triple-negative breast cancer. N. Engl. J. Med. 2010, 363:1938-1948.
5. Chang J.E., Seo S., Kim K.M., Werndli J.E., Bottner W.A., Rodrigues G.A., Sanchez F.A., Saphner T.J., Longo W.L., Kahl B.S. Rituximab and CHOP chemotherapy plus GM-CSF for previously untreated diffuse large B-cell lymphoma in the elderly: a Wisconsin oncology network study. Clin. Lymphoma Myeloma Leuk. 2010, 10:379-384.
6. Morales J.K., Kmieciak M., Knutson K.L., Bear H.D., Manjili M.H. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b-Gr1-bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res. Treat. 2010, 123:39-49.
7. Martinez M., Ono N., Planutiene M., Planutis K., Nelson E.L., Holcombe R.F. Granulocyte-macrophage stimulating factor (GM-CSF) increases circulating dendritic cells but does not abrogate suppression of adaptive cellular immunity in patients with metastatic colorectal cancer receiving chemotherapy. Cancer Cell. Int. 2012, 12:2.
8. Speiser D.E., Schwarz K., Baumgaertner P., Manolova V., Devevre E., Sterry W., Walden P., Zippelius A., Conzett K.B., Senti G., Voelter V., Cerottini J.P., Guggisberg D., Willers J., Geldhof C., Romero P., Kündig T., Knuth A., Dummer R., Trefzer U., Bachmann M.F. Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J. Immunother. 2010, 33:848-858.
9. Fuxman Bass J.I., Alvarez M.E., Gabelloni M.L., Vermeulen M.E., Amaral M.M., Geffner J.R., Trevani A.S. GM-CSF enhances a CpG-independent pathway of neutrophil activation triggered by bacterial DNA. Mol. Immunol. 2008, 46:37-44.
10. Ohashi K., Kobayashi G., Fang S., Zhu X., Antonia S.J., Krieg A.M., Sandler A.D. Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. J. Pediatr. Surg. 2006, 41:1361-1368.
11. Ohno S., Okuyama R., Aruga A., Sugiyama H., Yamamoto M. Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy. Anticancer Res. 2012, 32:2263-2269.
12. + CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood 2011, 118:3301-3310.
13. Zhong R., Teng J., Han B., Zhong H. Dendritic cells combining with cytokine-induced killer cells synergize chemotherapy in patients with late-stage non-small cell lung cancer. Cancer Immunol. Immunother. 2011, 60:1497-1502.
14. Sangiolo D. Cytokine induced killer cells as promising immunotherapy for solid tumors. J. Cancer 2011, 2:363-368.
15. Kim H.M., Kang J.S., Lim J., Kim J.Y., Kim Y.J., Lee S.J., Song S., Hong J.T., Kim Y., Han S.B. Antitumor activity of cytokine-induced killer cells in nude mouse xenograft model. Arch. Pharm. Res. 2009, 32:781-787.
16. Wang Y., Dai H., Li H., Lv H., Wang T., Fu X., Han W. Growth of human colorectal cancer SW1116 cells is inhibited by cytokine-induced killer cells. Clin. Dev. Immunol. 2011, 2011:621414.
17. Laport G.G., Sheehan K., Baker J., Armstrong R., Wong R.M., Lowsky R., Johnston L.J., Shizuru J.A., Miklos D., Arai S., Benjamin J.E., Weng W.K., Negrin R.S. Adoptive immunotherapy with cytokine-induced killer cells for patients with relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. Biol. Blood Marrow Transplant. 2011, 17:1679-1687.
18. Hontscha C., Borck Y., Zhou H., Messmer D., Schmidt-Wolf I.G. Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). J. Cancer Res. Clin. Oncol. 2011, 137:305-310.
19. He Q., Li J., Yin W., Song Z., Zhang Z., Yi T., Tang J., Wu D., Lu Y., Wang Z., Liu D., Zhang X., Hu Z., Gao J. Low-dose paclitaxel enhances the anti-tumor efficacy of GM-CSF surface-modified whole-tumor-cell vaccine in mouse model of prostate cancer. Cancer Immunol. Immunother. 2011, 60:715-730.
20. Zhang X., Shi X., Li J., Hu Z., Zhou D., Gao J., Tan W. A novel therapeutic vaccine of mouse GM-CSF surface modified MB49 cells against metastatic bladder cancer. J. Urol. 2012, 187:1071-1079.
21. Yang L., Ren B., Li H., Yu J., Cao S., Hao X., Ren X. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients. Cancer Immunol. Immunother. 2013, 62:65-73.
22. Hong S., Qian J., Li H., Yang J., Lu Y., Zheng Y., Yi Q. CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol. Immunother. 2012, 61:561-571.
23. Zhou P., Liang P., Dong B., Yu X., Han Z., Xu Y. Phase I clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma. Cancer Biol. Ther. 2011, 11:450-456.
24. Zhang D., Sun B., Zhao X., Cui Y., Xu S., Dong X., Che N. Mouse model for spontaneous basal-like breast cancer. Chin. J. Clin. Oncol. 2011, 38:1149-1153.
25. Jin J., Joo K.M., Lee S.J., Jo M.Y., Kim Y., Jin Y., Kim J.K., Ahn J.M., Yoon M.J., Lim J., Nam D.H. Synergistic therapeutic effects of cytokine-induced killer cells and temozolomide against glioblastoma. Oncol. Rep. 2011, 25:33-39.
26. Su X., Zhang L., Jin L., Ye J., Guan Z., Chen R., Guo T. Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma. Cancer Biother. Radiopharm. 2010, 25:465-470.
27. Li H., Wang C., Yu J., Cao S., Wei F., Zhang W., Han Y., Ren X.B. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery. Cytotherapy 2009, 11:1076-1083.
28. Szomolay B., Eubank T.D., Roberts R.D., Marsh C.B., Friedman A. Modeling the inhibition of breast cancer growth by GM-CSF. J. Theor. Biol. 2012, 303:141-151.
29. Rodriguez Salas N., Gonzalez Gonzalez E., Gamallo Amat C. Breast cancer stem cell hypothesis: clinical relevance (answering breast cancer clinical features). Clin. Transl. Oncol. 2010, 12:395-400.
30. Liu Z.Z., Chen P., Lu Z.D., Cui S.D., Dong Z.M. Enrichment of breast cancer stem cells using a keratinocyte serum-free medium. Chin. Med. J (Engl.) 2011, 124:2934-2936.
31. Barbieri F., Wurth R., Ratto A., Campanella C., Vito G., Thellung S., Daga A., Cilli M., Ferrari A., Florio T. Isolation of stem-like cells from spontaneous feline mammary carcinomas: phenotypic characterization and tumorigenic potential. Exp. Cell Res. 2012, 318:847-860.
32. Nishizawa S., Hirohashi Y., Torigoe T., Takahashi A., Tamura Y., Mori T., Kanaseki T., Kamiguchi K., Asanuma H., Morita R., Sokolovskaya A., Matsuzaki J., Yamada R., Fujii R., Kampinga H.H., Kondo T., Hasegawa T., Hara I., Sato N. HSP DNAJB8 controls tumor-initiating ability in renal cancer stem-like cells. Cancer Res. 2012, 72:2844-2854.
33. Jacquin J.P., Chargari C., Thorin J., Mille D., Mélis A., Orfeuvre H., Clavreul G., Chaigneau L., Nourissat A., Dumanoir C., Savary J., Merrouche Y., Magné N. Phase II trial of pegylated liposomal doxorubicin in combination with gemcitabine in metastatic breast cancer patients. Am. J. Clin. Oncol. 2012, 35:18-21.
34. Karmali R., Larson M.L., Wooldridge J.E., Gregory S.A., O'Brien T., Shammo J.M., Bueschel K., Venugopal P. Granulocyte-macrophage colony stimulating factor-induced immune priming of cyclophosphamide, doxorubicin, vincristine, and prednisone with rituximab chemoimmunotherapy in previously untreated patients with diffuse large B-cell lymphoma and mantle cell lymphoma. Leuk. Lymphoma 2011, 52:2097-2104.
35. Hansson L., Abdalla A.O., Moshfegh A., Choudhury A., Rabbani H., Nilsson B., Osterborg A., Mellstedt H. Long-term idiotype vaccination combined with interleukin-12 (IL-12), or IL-12 and granulocyte macrophage colony-stimulating factor, in early-stage multiple myeloma patients. Clin. Cancer Res. 2007, 13:1503-1510.
36. Schuster S.J., Venugopal P., Kern J.C., McLaughlin P. GM-CSF plus rituximab immunotherapy: translation of biologic mechanisms into therapy for indolent B-cell lymphomas. Leuk. Lymphoma 2008, 49:1681-1692.
37. Chu Y., Wang L.X., Yang G., Ross H.J., Urba W.J., Prell R., Jooss K., Xiong S., Hu H.M. Efficacy of GM-CSF-producing tumor vaccine after docetaxel chemotherapy in mice bearing established Lewis lung carcinoma. J. Immunother. 2006, 29:367-380.
38. Roche M.R., Rudd P.J., Krasner C.N., Matulonis U.A., Berlin S.T., Lee H., Silver M., Tran C.D., Seiden M.V., Penson R.T. Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors. Gynecol. Oncol. 2010, 116:168-172.
39. + dendritic cells. J. Immunol. 2011, 186:1503-1511.
40. Du H.Y., Xia S.Y., Song H.F., Li N., Shang M.M., Zou J., Wang Q.Q., Ou L., Sun X., Ji A.G., Tang Z.M. Structure efficacy relationships of immunostimulatory activity of CpG-containing oligodeoxynucleotides on mouse spleen cells. Acta Pharmacol. Sin. 2007, 28:1637-1644.
41. Ginzkey C., Eicker S.O., Marget M., Krause J., Brecht S., Westphal M., Hugo H.H., Mehdorn H.M., Steinmann J., Hamel W. Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model. Cancer Immunol. Immunother. 2010, 59:541-551.
42. Hong S., Qian J., Li H., Yang J., Lu Y., Zheng Y., Yi Q. CpG or IFN-a are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma. Cancer Immunol. Immunother. 2012, 61:561-571.
43. Saha A., Bhattacharya-Chatterjee M., Foon K.A., Celis E., Chatterjee S.K. Stimulatory effects of CpG oligodeoxynucleotide on dendritic cell-based immunotherapy of colon cancer in CEA/HLA-A2 transgenic mice. Int. J. Cancer 2009, 124:877-888.
44. Sharma S., Karakousis C.P., Takita H., Shin K., Brooks S.P. Intra-tumoral injection of CpG results in the inhibition of tumor growth in murine Colon-26 and B-16 tumors. Biotechnol. Lett. 2003, 25:149-153.
45. Hayashi F., Means T.K., Luster A.D. Toll-like receptors stimulate human neutrophil function. Blood 2003, 102:2660-2669.
46. Rettinger E., Kui S., Naumann I., Becker P., Kreyenberg H., Anzaghe M., Willasch A., Koehl U., Bug G., Ruthardt M., Klingebiel T., Fulda S., Bader P. The cytotoxic potential of interleukin-15-stimulated cytokine-induced killer cells against leukemia cells. Cytotherapy 2012, 14:91-103.
47. Kim H.M., Kang J.S., Lim J., Park S.K., Lee K., Yoon Y.D., Lee C.W., Lee K.H., Han G., Yang K.H., Kim Y.J., Kim Y., Han S.B. Inhibition of human ovarian tumor growth by cytokine-induced killer cells. Arch. Pharm. Res. 2007, 30:1464-1470.
48. Kim Y.J., Lim J., Kang J.S., Kim H.M., Lee H.K., Ryu H.S., Kim J.Y., Hong J.T., Kim Y., Han S.B. Adoptive immunotherapy of human gastric cancer with ex vivo expanded T cells. Arch. Pharm. Res. 2010, 33:1789-1795.
49. Anguille S., Willemen Y., Lion E., Smits E.L., Berneman Z.N. Dendritic cell vaccination in acute myeloid leukemia. Cytotherapy 2012, 14:647-656.